newsfilter
← Latest News
PR Newswire·

Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo

SNGX
  • The ongoing Bundibugyo virus outbreak in the Democratic Republic of Congo & Uganda was declared a Public Health Emergency of International Concern on May 16, 2026, with 80 deaths & 246 suspected cases as of May 15, 2026.
  • Soligenix, Inc. announced a collaboration with Dr. Axel Lehrer of the University of Hawaiʻi at Mānoa to develop a rapid vaccine formulation for the Bundibugyo virus using their existing platform.
  • Previous work demonstrated that the key Bundibugyo virus antigen is compatible with the CoVaccine HT™ adjuvant to create thermostable, protein-based subunit vaccines.
  • The ThermoVax® platform allows vaccines to be shipped at ambient temperatures & remain stable for at least 2 years at 40°C (104°F), eliminating the need for ultra-low cold-chain storage.
  • In preclinical studies, these filovirus vaccines induced broad immune responses in mice & provided up to 100% protection in non-human primates against lethal virus exposure.
  • Soligenix has received Orphan Drug Designation from the FDA for preventing & treating Sudan & Marburg orthoebolavirus infections, granting market exclusivity & regulatory benefits.
  • The company's Public Health Solutions segment includes vaccine candidates for ricin toxin, filoviruses, & COVID-19, supported by funding from NIAID, DTRA, & BARDA.
  • Soligenix halted its Phase 3 "FLASH2" study for HyBryte™ (SGX301) in April 2026 due to futility during an interim efficacy analysis, raising concerns about the company's ability to continue as a going concern without new capital or partnerships.
  • Currently, no approved vaccines exist for Sudan, Bundibugyo, or Marburg viruses, although approved vaccines for Ebola virus require stringent cold storage conditions.